Ps1572 Heart Disease and Pancreatic Iron in Thalassemia Major

Abstract

er in recipient-donor two loci HLA-mmtransplant compared to HLAmatched transplants (14.8% vs.4.2%, P = 0.049). Distribution of HLA mismatched loci and correlated effects on GVHD were shown in table 2. Patients receiving HLA-A mismatch HSCT had a significant higher risk of aGVHD grade II-IV (19.3% vs.6.5%, P = 0.003) as shown in figure4. DR+DQ mm (8/10 matched) transplant significantly correlated with increased aGVHD and cGVHD (33.3% vs.11.4%, 16.7% vs.3.9%,P = 0.006,0.019,respectively) as shown figure5.. Summary/Conclusion: Our data shows that donor and recipient gender disparity did not influence the risk of acute or chronic GVHD. Addition of ATG into the transplant regimen decreases the occurrence of cGVHD after PB-SCT. Patient received unrelated PBSC were associated with an increased aG-VHD. High serum ferritin level is also a risk factor of aGVHD for thlassemia patients.Mismatching at HLA-A and HLA-DR+DQ was associated with increased risk of both aGVHD and cGVHD. Older age is an independent risk factor for GVHD. We suggest that transplantation for β thalassemia major be performed before aged 9 years and iron chelation therapy pre-HSCT is necessary. Further studies on GVHD treatment should be highlighted.